YU55198A - Derivati 1,3,8-triaza-spiro/4,5/dekan-4-ona - Google Patents
Derivati 1,3,8-triaza-spiro/4,5/dekan-4-onaInfo
- Publication number
- YU55198A YU55198A YU55198A YU55198A YU55198A YU 55198 A YU55198 A YU 55198A YU 55198 A YU55198 A YU 55198A YU 55198 A YU55198 A YU 55198A YU 55198 A YU55198 A YU 55198A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- lower alkyl
- phenyl
- hydrogen
- cycloalkyl
- disturbance
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- -1 lower alcoxy Chemical group 0.000 abstract 2
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002648 azanetriyl group Chemical group *N(*)* 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 231100000863 loss of memory Toxicity 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Color Printing (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
Abstract
Ovaj pronalazak se odnosi na jedinjenja opste formule u kojoj oznacavaju R1 vodonik, nizi alkil, halogen, nizi alkoksi, trifluorometil, nizi alkil-fenil ili (C5-7)-cikloalkil, R2 vodonik, nizi alkil, fenil ili nizi alkil-fenil, R3 vodonik, nizi alkil, benzil, nizi alkil-fenil, nizi alkil-difenil, triazinil, cijanmetil, nizi alkil-piperidinil, nizi alkil-naftil, (C5-7)-cikloalkil, nizi alkil-(C5-7)-cikloalkil, nizi alkil-piridinil, nizi alkil-morfolinil, nizi alkil-dioksolanil, nizi alkil-oksazolil ili nizi alkil-2-okso-oksazolidinil i u kojoj prstenasti sistemi mogu bitisupstituisani dodatnim nizim alkilom, nizim alkoksi, trifluormetilom ili fenilom, ili oznacava -(CH2)nC(O)O-nizi alkil, -(CH2)nC(O)NH2, -(CH2)nC(O)N(nizi alkil)2, -(CH2)nOH ili -(CH2)nC(O)NHCH2C6H5, R4 vodonik, nizi alkil ili nitrilo, A prstenast sistem, koji se sastoji od (a) (C5-7)-cikloalkila, koji pored sa R4 opciono moze biti supstituisan nizim alkilom, trifluormetilom, fenilom, (C5-7)-cikloalkilom, spiro-undekanalkilom ili 2-norbornilom, ili oznacava jednu od sledecih grupa i pri cemu su R5 i R6 vodonik, nizi alkil ili uzeti zajedno i sa atomima ugljenika za koje su vezani formiraju fenil-prsten, R7 vodonik ili nizi alkil, isprekidana linija oznacava opcionu vezu i n 1 do 4, i na njihove farmaceutski prihvatljive kiselinske adicione soli. Jedinjenja d ata ovim pronalaskom su agonisti i/ili antagonisti Orfanin FQ (OFQ) receptora. Kao posledica toga ona se mogu koristiti u lecenju nedostataka pamcenja i paznje, psihijatrijskih, neuroloskih i fizioloskih poremecaja, narocito, ali nisu ogranicena samo na to, poboljsanja simptoma uznemirenosti (anksioznosti) i stresnih poremecaja, depresije, traume, gubitka pamcenja prouzrokovanog Alchajmerovom bolescu ili drugim demencijama (slaboumnostima), epilepsije i konvulzija, akutnih i/ili hronicnih stanja bola, simptoma zavisnosti od lekova, kontrole ravnoteze vode, izlucivanja Na+, poremecaja arterijskog krvnog pritiska i metabolickih poremecaja kao sto je gojaznost.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97121427 | 1997-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU55198A true YU55198A (sh) | 2001-12-26 |
Family
ID=8227753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU55198A YU55198A (sh) | 1997-12-05 | 1998-12-03 | Derivati 1,3,8-triaza-spiro/4,5/dekan-4-ona |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6043366A (sh) |
| JP (1) | JP3366868B2 (sh) |
| KR (1) | KR19990062800A (sh) |
| CN (1) | CN1118467C (sh) |
| AR (1) | AR016428A1 (sh) |
| AT (1) | ATE212635T1 (sh) |
| AU (1) | AU744338B2 (sh) |
| BR (1) | BR9805297B1 (sh) |
| CA (1) | CA2255171C (sh) |
| CO (1) | CO4990965A1 (sh) |
| CZ (1) | CZ399698A3 (sh) |
| DE (1) | DE69803653T2 (sh) |
| DK (1) | DK0921125T3 (sh) |
| ES (1) | ES2170446T3 (sh) |
| HR (1) | HRP980613A2 (sh) |
| HU (1) | HUP9802807A3 (sh) |
| ID (1) | ID21413A (sh) |
| IL (1) | IL127399A0 (sh) |
| MA (1) | MA26573A1 (sh) |
| NO (1) | NO312161B1 (sh) |
| NZ (1) | NZ333159A (sh) |
| PE (1) | PE135299A1 (sh) |
| PL (1) | PL330062A1 (sh) |
| PT (1) | PT921125E (sh) |
| SG (1) | SG71173A1 (sh) |
| TR (1) | TR199802520A2 (sh) |
| TW (1) | TW408123B (sh) |
| YU (1) | YU55198A (sh) |
| ZA (1) | ZA9811128B (sh) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2237047T3 (es) * | 1998-10-23 | 2005-07-16 | Pfizer Inc. | Compuestos de 1,3,8-triazaespiro(4,5)decanona como agonistas del receptor orl1. |
| DE60033071T2 (de) * | 1999-12-06 | 2007-08-23 | Euro-Celtique S.A. | Triazospiroverbindungen mit nociceptin-rezeptoraffinität |
| CA2454785C (en) * | 2001-07-23 | 2010-09-07 | Banyu Pharmaceutical Co., Ltd. | 4-oxoimidazolidine-2-spiropiperidine derivatives |
| PT1491212E (pt) * | 2002-03-29 | 2012-11-16 | Mitsubishi Tanabe Pharma Corp | Medicamento para distúrbios de sono |
| EA009369B1 (ru) * | 2002-09-09 | 2007-12-28 | Янссен Фармацевтика, Н.В. | Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором |
| AU2003299791A1 (en) * | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
| NZ544282A (en) * | 2003-05-23 | 2009-07-31 | Zealand Pharma As | Triaza-spiro compounds as nociceptin analogues and uses thereof |
| US20060178390A1 (en) * | 2004-08-02 | 2006-08-10 | Alfonzo Jordan | 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| CN101146801A (zh) * | 2005-03-22 | 2008-03-19 | 霍夫曼-拉罗奇有限公司 | 新型的dpp-iv抑制剂的盐和多晶型物 |
| JP2009541342A (ja) * | 2006-06-20 | 2009-11-26 | ワイス | Ｋｖ１．５カリウムチャネル阻害剤 |
| EA200970517A1 (ru) * | 2006-11-28 | 2009-12-30 | Янссен Фармацевтика Н.В. | Соли 3-(3-амино-2-(r)-гидроксипропил)-1-(4-фторфенил)-8-(8-метилнафталин-1-илметил)-1,3,8-триазаспиро[4,5]декан-4-она |
| CA2679530C (en) * | 2007-03-01 | 2012-09-25 | Mitsubishi Tanabe Pharma Corporation | Benzimidazole compound and pharmaceutical use thereof |
| MX2009011006A (es) * | 2007-04-09 | 2009-11-02 | Janssen Pharmaceutica Nv | Derivados de 1,3,8-trisustituido-1,3,8-triaza-espiro[4.5]decano-4- ona como ligandos del receptor de orl-1 para el tratamiento de ansiedad y depresion. |
| PA8801401A1 (es) * | 2007-10-25 | 2009-05-15 | Janssen Pharmaceutica Nv | Arilindenopirimidinas y su uso como adenosina a2a |
| TW201016675A (en) * | 2008-09-16 | 2010-05-01 | Mitsubishi Tanabe Pharma Corp | Crystalline benzoimidazole compound and salt thereof |
| US20100076003A1 (en) * | 2008-09-19 | 2010-03-25 | Kathleen Battista | 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators |
| WO2010037081A1 (en) * | 2008-09-29 | 2010-04-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific spiro-piperidine compounds |
| CN102459278A (zh) | 2009-06-16 | 2012-05-16 | 默沙东公司 | 取代的-1,3,8-三氮杂螺[4.5]癸烷-2,4-二酮 |
| CN107849044B (zh) * | 2015-07-03 | 2021-06-25 | 豪夫迈·罗氏有限公司 | 作为ddr1抑制剂的三氮杂-螺癸酮类化合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155669A (en) * | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 2, 4, 8-triaza-spiro (4, 5) dec-2-enes |
| US3155670A (en) * | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
| US3161644A (en) * | 1962-06-22 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-benzyl-4-substituted piperidines |
| US3238216A (en) * | 1963-06-20 | 1966-03-01 | Res Lab Dr C Janssen N V | Substituted 1, 3, 8-triaza-spiro (4, 5) decanes |
| JPS5212171A (en) * | 1975-07-17 | 1977-01-29 | Yoshitomi Pharmaceut Ind Ltd | Process for preparation of cyclohexane derivatives |
| JPS51100084A (sh) * | 1975-02-28 | 1976-09-03 | Yoshitomi Pharmaceutical | |
| GB1486546A (en) * | 1975-02-28 | 1977-09-21 | Yoshitomo Pharma Ind Ltd | 4,4-diphenyl-cyclohexylpiperidine compounds and analogues thereof |
| JPS5934713B2 (ja) * | 1976-01-05 | 1984-08-24 | ウェルファイド株式会社 | 脂環式誘導体 |
| US4076821A (en) * | 1976-02-27 | 1978-02-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof |
| US4329353A (en) * | 1980-10-22 | 1982-05-11 | Janssen Pharmaceutica, N.V. | 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof |
| MA19091A1 (fr) * | 1980-03-10 | 1981-10-01 | Janssen Pharmaceutica Nv | Nouveaux derives de i-(4-aryl-cyclohexyl)piperidine . |
| GR73633B (sh) * | 1980-03-10 | 1984-03-26 | Janssen Pharmaceutica Nv | |
| EP0114787B1 (de) * | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
| JPS6012357B2 (ja) * | 1984-01-23 | 1985-04-01 | 吉富製薬株式会社 | 脂環式誘導体 |
| CA2226058C (en) * | 1997-01-30 | 2008-01-29 | F. Hoffmann-La Roche Ag | 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives |
-
1998
- 1998-11-27 PT PT98122511T patent/PT921125E/pt unknown
- 1998-11-27 DE DE69803653T patent/DE69803653T2/de not_active Expired - Lifetime
- 1998-11-27 DK DK98122511T patent/DK0921125T3/da active
- 1998-11-27 AT AT98122511T patent/ATE212635T1/de active
- 1998-11-27 ES ES98122511T patent/ES2170446T3/es not_active Expired - Lifetime
- 1998-12-03 US US09/204,184 patent/US6043366A/en not_active Expired - Fee Related
- 1998-12-03 SG SG1998005141A patent/SG71173A1/en unknown
- 1998-12-03 AR ARP980106141A patent/AR016428A1/es active IP Right Grant
- 1998-12-03 PE PE1998001176A patent/PE135299A1/es not_active Application Discontinuation
- 1998-12-03 PL PL98330062A patent/PL330062A1/xx unknown
- 1998-12-03 ID IDP981576A patent/ID21413A/id unknown
- 1998-12-03 CA CA002255171A patent/CA2255171C/en not_active Expired - Fee Related
- 1998-12-03 YU YU55198A patent/YU55198A/sh unknown
- 1998-12-03 NZ NZ333159A patent/NZ333159A/en unknown
- 1998-12-04 JP JP34527898A patent/JP3366868B2/ja not_active Expired - Fee Related
- 1998-12-04 TR TR1998/02520A patent/TR199802520A2/xx unknown
- 1998-12-04 HU HU9802807A patent/HUP9802807A3/hu unknown
- 1998-12-04 MA MA25369A patent/MA26573A1/fr unknown
- 1998-12-04 KR KR1019980053080A patent/KR19990062800A/ko active Search and Examination
- 1998-12-04 ZA ZA9811128A patent/ZA9811128B/xx unknown
- 1998-12-04 BR BRPI9805297-7A patent/BR9805297B1/pt not_active IP Right Cessation
- 1998-12-04 TW TW087120132A patent/TW408123B/zh not_active IP Right Cessation
- 1998-12-04 IL IL12739998A patent/IL127399A0/xx unknown
- 1998-12-04 CO CO98072457A patent/CO4990965A1/es unknown
- 1998-12-04 HR HR97121427.5A patent/HRP980613A2/hr not_active Application Discontinuation
- 1998-12-04 CZ CZ983996A patent/CZ399698A3/cs unknown
- 1998-12-04 CN CN98122759A patent/CN1118467C/zh not_active Expired - Fee Related
- 1998-12-04 NO NO19985684A patent/NO312161B1/no not_active IP Right Cessation
- 1998-12-04 AU AU96087/98A patent/AU744338B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU55198A (sh) | Derivati 1,3,8-triaza-spiro/4,5/dekan-4-ona | |
| GR3034498T3 (en) | Substituted benzylaminoquinuclidines as substance p antagonists. | |
| DE3662896D1 (en) | 21-substituted thiosteroids | |
| HK1108312A1 (en) | Medical use and composition for the treatment of lipid and glucose metabolism disorders | |
| ATE248852T1 (de) | Sterolderivate für die regulierung der meiose | |
| GT200000226A (es) | Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias. | |
| BG103249A (en) | Application of sibutramine analogues for reducing lipid levels | |
| BG103143A (en) | Substituted pyrido- or pirimidocontaining 6,6- or 6,7-bicyclic derivatives | |
| ES265523U (es) | "abrazadera para tubos". | |
| ZA955868B (en) | Substituted pyrimidine compounds and the use thereof | |
| NO993240D0 (no) | 3-arylsubstituerte pyrazolo[4,3-d]pyrimidinderivater, samt kortikotropinfrigj°ringsfaktor reseptor (CRF1) spesifikke ligander | |
| GR78410B (sh) | ||
| ES475514A1 (es) | Un procedimiento para la preparacion de nuevos derivados de fenilglicina | |
| DE69520747D1 (de) | Ergonomischer sitz für fahrrad | |
| BR0312610A (pt) | Célula com eletrodo de leito eruptivo para eletrodeposição de metais | |
| ATE300870T1 (de) | Rolleneinheit für angelrolle | |
| CA2137961A1 (en) | Cyclic depsipeptides having 18 ring atoms, and their use for combating endoparasites | |
| CN220349912U (zh) | 一种穿戴式水下推进设备 | |
| CN217532636U (zh) | 一种预连接结构和座椅靠背 | |
| SE9604522L (sv) | Kikare med möjlighet att tillfälligt frysa bilden | |
| FR2431260A1 (fr) | Melange nutritif destine a l'alimentation du betail | |
| CA1264325C (en) | AROYLIMIDAZOLONES | |
| ATE137215T1 (de) | 2-(2,3-dicarboxycyclopropyl)-glycin und ein verfahren zu ihrer herstellung | |
| ES467791A1 (es) | Procedimiento para la obtencion de nuevos derivados del 1- fenil-2-amino-1,3-propandiol-n-alcohilo. | |
| Roebert | How to reduce conflict in water management: Employ new resources or change existing habits. National report: The Netherlands |